Related Experiment Video
Updated: May 15, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
CROI 2026: Advances in Epidemiology and Treatment of Viral Hepatitis
1Columbia University Irving Medical Center, New York, NY, USA.
Abstract:
The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hepatitis B outcomes in people with HIV on non-hepatitis B-active regimens. Advances in hepatitis B treatment were covered, with some abstracts highlighting novel investigational agents such as antivirals or immune modulators. Data were presented from a phase III trial examining the safety and efficacy of bulevirtide, an investigational agent for hepatitis D treatment. Pharmacokinetic data in animal models from a long-acting injectable intraparticle coformulation of glecaprevir/pibrentasvir were presented for the treatment of hepatitis C. Several abstracts highlighted interventions to increase hepatitis C virus infection detection rates, such as rapid or point-of-care testing, and others focused on improving linkage to care to increase hepatitis C treatment and sustained virologic response rates. Finally, a single abstract showed 2 investigational agents with antiviral activity for hepatitis E virus infection.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Human Virome
Inhibitors of Viral Protein Synthesis
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Microorganisms in Medicine and Therapeutics

